ICMR sets up a task force on gene therapy research

Our Bureau New Delhi | Updated on December 14, 2019 Published on December 14, 2019

Indian Council of Medical Research (ICMR) is setting up a task force on gene therapy research to encourage research in the emerging field.

The research body among other things has proposed forming the task force to explore gene editing based therapeutic approaches to treat illnesses.

In a call for research proposals, ICMR has stressed that many inherited disorders are not treated by current available drugs or traditional therapies.

Gene Therapy refers to the process of introduction, removal or change in content of an individual’s genetic material with the goal of treating the disease and a possibility of achieving long term cure.

While the western world has made considerable strides with regards to gene therapy over the past 30 years, ICMR stated that drugs like Luxuturna for Retinitis Pigmentosa, a condition which leads to breakdown of retinal cells in the eye, and leads to low vision, or Yescarta which is a cell therapy for cancer, are currently in clinical trial phase.

“However for the vast majority of inherited diseases, appropriate targeted therapies are yet unavailable despite the large load of genetic disease in our population. To address this particular gap, ICMR is inviting proposals to fund gene therapy research projects,” the research body has said in it’s circular.

ICMR has narrowed down on genetic diseases affecting the brain and muscles, eye disorders affecting the retina and cornea, heart diseases and blood disorders like Thalassemia, Sickle Cell Disease and Haemophilia. It has also stressed on diseases like Cancer, Diabetes and Lung diseases. “The strategies proposed shuold have a possibility of translation into future human trials,” the circular states.

In recently released guidelines on gene therapy ICMR stated, “India has large burden of genetic disorders and unmet medical needs and gene therapy can prove to be a turning point in treatment of such disorders. However, it also brings along with it unique technical risks and ethical challenges. Creation of babies using germline gene editing by a Chinese scientist recently, attracted global criticism and fuelled a debate on ethical concerns regarding applications of gene therapy technologies. This also brought to forefront the requirement of stringent guidelines and regulations to prevent misuse and premature commercialization.”

It further said, “Many countries around the world have developed rules and guidelines to regulate gene therapy trials. Taking cognizance of situation, it was felt necessary to frame national guidelines and regulations to direct scientists and clinicians including industry regarding the procedures and requirements to be followed for performing gene therapy in India.”

Published on December 14, 2019

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.